Small molecules remain central to pharmaceutical innovation, but the development process is changing. More complex chemistry, difficult physical properties, accelerated timelines, and rising regulatory expectations are placing added pressure on development teams and their outsourcing partners.
This eBook from Contract Pharma and Lonza explores the challenges and priorities shaping modern small molecule development. It includes findings from an industry survey of 180 pharmaceutical professionals, a visual summary of the key results, an expert Q&A with one of Lonza’s small molecule experts, and an overview of the trends influencing process development, scale-up, technology adoption, and CDMO selection.
Key insights include:
See why small molecules are getting harder to make, even as timelines get shorter.
Spot the scale-up and process problems that trip up programs most often.
Understand where new tech, like AI and digital tools, fits into small molecule development.
Lonza's David Hall discusses how rising molecular complexity, accelerated timelines, and new technologies are reshaping small molecule development and outsourcing strategies.
